Diazepam in Pregnancy
Diazepam should be avoided during pregnancy whenever possible, but when maternal psychiatric stability requires benzodiazepine therapy, use the lowest effective dose for the shortest duration with careful risk-benefit discussion, recognizing that untreated maternal anxiety also poses risks to pregnancy outcomes. 1
Key Safety Considerations
Fetal and Neonatal Risks
Diazepam use during pregnancy carries several documented risks:
- No increased risk of major congenital malformations - Current evidence does not support an association with structural birth defects 1, 2
- Increased risk of adverse pregnancy outcomes including miscarriage (OR 1.58-1.83), preterm birth (RR 1.20), and low birth weight 1, 3, 4
- Neonatal withdrawal syndrome occurs in 20-40% of exposed neonates, presenting with irritability, abnormal muscle tone, poor feeding, and respiratory distress 1
- Floppy infant syndrome may occur with third-trimester exposure, characterized by hypotonia, lethargy, low Apgar scores, and CNS depression 1
Both neonatal withdrawal and floppy infant syndrome typically present within hours of birth and persist up to 14 days 1.
Critical Nuance: Untreated Illness Also Poses Risks
The decision is not simply "use versus don't use" - untreated maternal anxiety, mood, and sleep disorders carry similar risks including miscarriage, preterm birth, and low birth weight 1. The 2025 joint clinical practice guideline explicitly states that if tapering precipitates reemergence of severe anxiety, continuation benefits may outweigh risks 1.
Clinical Decision Algorithm
Step 1: Optimize Non-Pharmacological Approaches First
- Prioritize cognitive behavioral therapy (CBT) and CBT for insomnia (CBT-I) 1
- These should be first-line interventions when feasible
Step 2: If Benzodiazepine Therapy Is Necessary
Lorazepam is generally preferred over diazepam due to lack of active metabolites and lower relative infant dose, though switching is not mandatory if a patient is stable on diazepam 1. Consider transitioning from alprazolam to lorazepam if currently prescribed 1.
Prescribe at the lowest effective dose with consideration of pregnancy-related pharmacokinetic changes 1
Use for the shortest possible duration - avoid chronic use throughout pregnancy 1
Step 3: Shared Decision-Making
Engage in detailed discussion of:
- Maternal risks of untreated psychiatric illness
- Fetal risks of medication exposure
- Individual patient circumstances and severity of symptoms
- The patient's unique needs and preferences 1
Step 4: If Tapering Is Considered
Tapering can be done safely during pregnancy 1, but must be balanced against risk of psychiatric decompensation 1
Use hyperbolic (proportionate) tapering rather than linear reductions - reduce by small percentages of the current dose (e.g., 5-10% monthly) to minimize withdrawal symptoms 5
Monitor closely for psychiatric symptom evolution, as pregnancy and postpartum metabolism shifts can rapidly change medication effects 1
Essential Management Steps
During Pregnancy
- Coordinate care between the prescribing clinician and prenatal care provider 1
- Consider consultation with reproductive psychiatry specialists 1
- Monitor psychiatric symptoms closely throughout pregnancy 1
At Delivery
- Communicate benzodiazepine exposure to the infant's healthcare team (with parental consent) 1
- Monitor neonate for signs of withdrawal and floppy infant syndrome 6
- Encourage breastfeeding - this can substantially delay onset and reduce severity of neonatal abstinence syndrome, decrease need for pharmacologic treatment, and shorten hospitalization 1
Common Pitfalls to Avoid
Abrupt discontinuation - Never stop benzodiazepines suddenly in pregnancy; this can precipitate severe maternal anxiety and potentially life-threatening withdrawal 6
Assuming all benzodiazepines are equally risky - While class effects exist, lorazepam has specific advantages in pregnancy 1
Ignoring maternal psychiatric stability - The risk-benefit calculation must include consequences of untreated illness 1
Linear dose reductions when tapering - These produce escalating withdrawal effects; use proportionate reductions instead 5
FDA Labeling Warnings
The FDA label for diazepam specifically warns that late pregnancy use can result in neonatal sedation (respiratory depression, lethargy, hypotonia) and withdrawal symptoms (hyperreflexia, irritability, tremors, feeding difficulties) 6. Neonates must be monitored accordingly.
Evidence Quality Note
The most recent and comprehensive guidance comes from the 2025 joint clinical practice guideline on benzodiazepine tapering 1, which provides strong recommendations based on clinical consensus. Recent meta-analyses (2024-2026) confirm associations with adverse outcomes but also highlight methodological limitations including confounding by indication 7, 3, 4. Older studies (2002-2003) suggested relative safety 8, 9, 10, but more recent large-scale data reveals more nuanced risks.